Related references
Note: Only part of the references are listed.A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Joseph J. Eron et al.
AIDS (2018)
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Chloe Orkin et al.
LANCET HIV (2018)
Single-Tablet Regimens for the Treatment of HIV-I Infection
Jamielynn C. Sebaaly et al.
ANNALS OF PHARMACOTHERAPY (2017)
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens
D. Armenia et al.
HIV MEDICINE (2017)
HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies
Erkki Lathouwers et al.
HIV CLINICAL TRIALS (2017)
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
Adrian S. Ray et al.
ANTIVIRAL RESEARCH (2016)
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
Erik De Clercq
BIOCHEMICAL PHARMACOLOGY (2016)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
Sarah L. Greig et al.
DRUGS (2016)
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
Kate El Bouzidi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate
Christian Callebaut et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
Jose R. Santos et al.
CLINICAL INFECTIOUS DISEASES (2015)
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Anthony Mills et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors
Rujuta A. Bam et al.
ANTIVIRAL THERAPY (2014)
Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection
Emma D. Deeks
DRUGS (2014)
Darunavir: A Review of Its Use in the Management of HIV-1 Infection
Emma D. Deeks
DRUGS (2014)
Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatmentexperienced patients
Erkki Lathouwers et al.
ANTIVIRAL THERAPY (2013)
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial
C. Orkin et al.
HIV MEDICINE (2013)
Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults
Peter J. Ruane et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection
Bhavik M. Shah et al.
PHARMACOTHERAPY (2013)
Week 96 Efficacy, Virology and Safety of Darunavir/r Versus Lopinavir/r in Treatment-Experienced Patients in TITAN
Denes Banhegyi et al.
CURRENT HIV RESEARCH (2012)
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
Sonia Rodriguez-Novoa et al.
AIDS (2010)
Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy
Eva Poveda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
Lianhong Xu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Resistance profile of darunavir:: Combined 24-week results from the POWER trials
Sandra de Meyer et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
Mechanism of active renal tubular efflux of tenofovir
Adrian S. Ray et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue
WA Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Emtricitabine - A review of its use in the management of HIV infection
JE Frampton et al.
DRUGS (2005)
Share Paper
